APA (7th ed.) Citation

Wang, W., Shao, L., Xu, Y., Song, Z., Lou, G., Zhang, Y., & Chen, M. (2022). Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: A retrospective study. BMC.

Chicago Style (17th ed.) Citation

Wang, Wenxian, Lan Shao, Yibing Xu, Zhengbo Song, Guangyuan Lou, Yiping Zhang, and Ming Chen. Efficacy and Safety of Anlotinib with and Without EGFR-TKIs or Immunotherapy in the Treatment of Elder Patients with Non-small-cell Lung Cancer: A Retrospective Study. BMC, 2022.

MLA (9th ed.) Citation

Wang, Wenxian, et al. Efficacy and Safety of Anlotinib with and Without EGFR-TKIs or Immunotherapy in the Treatment of Elder Patients with Non-small-cell Lung Cancer: A Retrospective Study. BMC, 2022.